Emergence of Drug Resistance during an Influenza Epidemic: Insights from a Mathematical Model
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A model was developed for the emergence of drug-resistant influenza viruses during a closed population influenza epidemic that occurs in a single wave. The model was used to consider several treatment and chemoprophylaxis strategies and to determine their effects on the spread of the infection. The model predicts frequent emergence and transmission of drug-resistant viruses with certain treatment scenarios. According to the model, chemoprophylaxis of susceptible persons (without treatment of those who are symptomatic) may be the best way to reduce the force of an epidemic and to keep development of drug resistance low. The model predictions indicate that the relative transmissibility of resistant variants compared with wild type virus and the choice of the treatment or chemoprophylaxis strategy can be decisive for the spread of drug-resistant viruses, a feature that may be crucial in a pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
Dolin, R., Reichman, R. C., Madore, H. P., Maynard, R., Linton, P. N., & Webber-Jones, J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209023071002 · Cited by 501 · cited 2×
“10 epi [25]; 0.”
Background
Cited by
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179
Self-citationAustin, D. J., Kristinsson, K. G., & Anderson, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.3.1152 · Cited by 784
Containing Pandemic Influenza with Antiviral Agents
Longini, I. M. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh092 · Cited by 705
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1)
Coburn, B. J., Wagner, B. G., & Blower, S. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-30 · Cited by 373
Antiviral Resistance and the Control of Pandemic Influenza
Lipsitch, M., Cohen, T., Murray, M., & Levin, B. R. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040015 · Cited by 209
“These results extend those of previous models, which showed (like our model) that the fitness cost of resistance strongly influences the ability of resistant strains to spread during an epidemic [10–12].”
BackgroundResultAustin, D. J., & Anderson, R. M. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0425 · Cited by 195
“Very few papers in this important ¢eld address the key population genetic issues that underpin an understanding of the evolution and spread of resistant organisms (Bjo« rkmann et al. 1998; Stilianakis et al. 1998; Blower et al. 1998; Levin et al. 1997; Austin et al. 1997a,b; Bonhoe¡er et al. 1997; Schrag et al. 1997;…”
BackgroundWhat is the best control strategy for multiple infectious disease outbreaks?
Handel, A., Longini, I. M., & Antia, R. (2007) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2006.0015 · Cited by 94
“For a fast evolving pathogen, such as influenza, the potential emergence of drug resistance could pose a serious problem (Stilianakis et al. 1998; Regoes & Bonhoeffer 2006; Lipsitch et al. in press).”
Background
Metadata
- Authors
- Stilianakis, N. I., Perelson, A. S., & Hayden, F. G.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-04-01
- Volume
- 177
- Issue
- 4
- Pages
- 863-873
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2326216123
- Cited by
- 127
- References
- 1
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.